Drug Profile
MDL 63042
Alternative Names: A-40,926Latest Information Update: 06 Feb 2017
Price :
$50
*
At a glance
- Originator Biosearch Italia
- Class Antibacterials; Glycopeptides
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 06 Feb 2017 Discontinued - Preclinical for Bacterial infections in Italy (unspecified route)
- 30 Sep 2005 Vicuron Pharmaceuticals has since been acquired by and merged into Pfizer
- 14 Jul 1998 No-Development-Reported for Bacterial infections in Italy (Unknown route)